WallStSmart

Haoxi Health Technology Limited Class A Ordinary Shares (HAO)vsNebius Group N.V. (NBIS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Nebius Group N.V. generates 1957% more annual revenue ($877.90M vs $42.68M). NBIS leads profitability with a 93.1% profit margin vs -6.5%. NBIS earns a higher WallStSmart Score of 55/100 (C-).

HAO

Hold

49

out of 100

Grade: D+

Growth: 8.7Profit: 2.0Value: 5.0Quality: 9.0
Piotroski: 4/9Altman Z: 5.80

NBIS

Buy

55

out of 100

Grade: C-

Growth: 8.0Profit: 5.0Value: 6.0Quality: 5.5
Piotroski: 5/9Altman Z: 0.92
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for HAO.

NBISUndervalued (+26.0%)

Margin of Safety

+26.0%

Fair Value

$307.91

Current Price

$227.81

$80.10 discount

UndervaluedFair: $307.91Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HAO5 strengths · Avg: 9.8/10
Price/BookValuation
0.0x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
41.2%10/10

Revenue surging 41.2% year-over-year

EPS GrowthGrowth
172.7%10/10

Earnings expanding 172.7% YoY

Altman Z-ScoreHealth
5.8010/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

NBIS4 strengths · Avg: 9.3/10
Profit MarginProfitability
93.1%10/10

Keeps 93 of every $100 in revenue as profit

Revenue GrowthGrowth
684.0%10/10

Revenue surging 684.0% year-over-year

Market CapQuality
$66.16B9/10

Large-cap with strong market position

PEG RatioValuation
0.638/10

Growing faster than its price suggests

Areas to Watch

HAO4 concerns · Avg: 2.0/10
Market CapQuality
$1.97M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-15.5%2/10

ROE of -15.5% — below average capital efficiency

Free Cash FlowQuality
$-2.27M2/10

Negative free cash flow — burning cash

Profit MarginProfitability
-6.5%1/10

Currently unprofitable

NBIS4 concerns · Avg: 3.3/10
Price/BookValuation
8.1x4/10

Trading at 8.1x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Debt/EquityHealth
1.313/10

Elevated debt levels

P/E RatioValuation
101.0x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : HAO

The strongest argument for HAO centers on Price/Book, Revenue Growth, EPS Growth. Revenue growth of 41.2% demonstrates continued momentum.

Bull Case : NBIS

The strongest argument for NBIS centers on Profit Margin, Revenue Growth, Market Cap. Profitability is solid with margins at 93.1% and operating margin at -32.1%. Revenue growth of 684.0% demonstrates continued momentum.

Bear Case : HAO

The primary concerns for HAO are Market Cap, Return on Equity, Free Cash Flow.

Bear Case : NBIS

The primary concerns for NBIS are Price/Book, EPS Growth, Debt/Equity. A P/E of 101.0x leaves little room for execution misses.

Key Dynamics to Monitor

HAO profiles as a hypergrowth stock while NBIS is a growth play — different risk/reward profiles.

NBIS carries more volatility with a beta of 1.24 — expect wider price swings.

NBIS is growing revenue faster at 684.0% — sustainability is the question.

HAO generates stronger free cash flow (-2M), providing more financial flexibility.

Bottom Line

NBIS scores higher overall (55/100 vs 49/100), backed by strong 93.1% margins and 684.0% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Haoxi Health Technology Limited Class A Ordinary Shares

COMMUNICATION SERVICES · ADVERTISING AGENCIES · USA

Haoxi Health Technology Limited Class A Ordinary Shares is a pioneering force in the health technology sector, focused on revolutionizing healthcare delivery through innovative solutions. Utilizing advanced technologies, including artificial intelligence and data analytics, the company significantly improves diagnostic accuracy, treatment efficiency, and patient management. With a robust commitment to research and development, Haoxi is well-positioned to capitalize on emerging trends in healthcare technology, presenting considerable growth opportunities for institutional investors looking to engage in this dynamic market.

Nebius Group N.V.

COMMUNICATION SERVICES · INTERNET CONTENT & INFORMATION · USA

Nebius Group N.V. (Ticker: NBIS) is a forward-looking technology company specializing in advanced digital solutions designed to enhance client engagement and streamline operational efficiency across diverse sectors. By harnessing the power of cloud computing, artificial intelligence, and data analytics, Nebius equips businesses to effectively manage the complexities of the digital age. With a strong portfolio of intellectual property and meaningful strategic partnerships, the company is poised to capture significant growth opportunities in the dynamic technology landscape, positioning itself as an appealing investment choice for institutional investors seeking high-growth prospects in tech-driven markets.

Visit Website →

Want to dig deeper into these stocks?